Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer

Cancer

Volumn 118, Issue 9, 2012, Pages 2454-2465

  Kim, Jin Soo ^a   Kim, Edward S ^a   Liu, Diane ^a   Lee, J Jack ^a   Solis, Luisa ^a   Behrens, Carmen ^a   Lippman, Scott M ^a   Hong, Waun Ki ^a   Wistuba, Ignacio I ^a   Lee, Ho Young ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b Seoul National University   (South Korea)

Author keywords

carcinoma; IGF type 1; insulin; nonsmall cell lung; prognosis; receptor; survival

Indexed keywords

INSULIN RECEPTOR; SOMATOMEDIN C RECEPTOR; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SCORING SYSTEM; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN;

EID: 84857380018     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26492     Document Type: Article

References (38)

1. Janku F, Stewart DJ, Kurzrock R,. Targeted therapy in non-small cell lung cancer-is it becoming a reality? Nat Rev Clin Oncol. 2010; 7: 401-414.
2. Pollak M,. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008; 8: 915-928.
3. Ryan PD, Goss PE,. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist. 2008; 13: 16-24.
4. Camidge DR, Dziadziuszko R, Hirsch FR,. The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers. Clin Lung Cancer. 2009; 10: 262-272.
5. Frasca F, Pandini G, Sciacca L, et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem. 2008; 114: 23-37.
6. Denley A, Wallace JC, Cosgrove LJ, Forbes BE,. The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: a review. Horm Metab Res. 2003; 35: 778-785.
7. Mathieu MC, Clark GM, Allred DC, Goldfine ID, Vigneri R,. Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians. 1997; 109: 565-571.
8. Law JH, Habibi G, Hu K, et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 2008; 68: 10238-10246.
9. Novosyadlyy R, Vijayakumar A, Lann D, Fierz Y, Kurshan N, LeRoith D,. Physical and functional interaction between polyoma virus middle T antigen and insulin and IGF-I receptors is required for oncogene activation and tumour initiation. Oncogene. 2009; 28: 3477-3486.
10. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R,. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev. 2009; 30: 586-623.
11. Ma J, Li H, Giovannucci E, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer- specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008; 9: 1039-1047.
12. Cappuzzo F, Tallini G, Finocchiaro G, et al. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Ann Oncol. 2010; 21: 562-527.
13. Gong Y, Yao E, Shen R, et al. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One. 2009; 4: e7273.
14. Dziadziuszko R, Merrick DT, Witta SE, et al. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol. 2010; 28: 2174-2180.
15. Chang MH, Lee J, Han J, et al. Prognostic role of insulin- like growth factor receptor-1 expression in small cell lung cancer. APMIS. 2009; 117: 861-869.
16. Herbst RS, Heymach JV, Lippman SM,. Lung cancer. N Engl J Med. 2008; 359: 1367-1380.
17. Kim SJ, Rabbani ZN, Dong F, et al. Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. Med Oncol. 2010; 27: 91-97.
18. Yuan P, Kadara H, Behrens C, et al. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One. 2010; 5: e9112.
19. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC,. Tumours of the lung. In:, Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon: International Agency for Research on Cancer (IARC); 2004: 9-124.
20. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006; 439: 353-357.
21. Lee ES, Son DS, Kim SH, et al. Prediction of recurrence- free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res. 2008; 14: 7397-7404.
22. Zhang H, Fagan DH, Zeng X, Freeman KT, Sachdev D, Yee D,. Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene. 2010; 29: 2517-2527.
23. Cox ME, Gleave ME, Zakikhani M, et al. Insulin receptor expression by human prostate cancers. Prostate. 2009; 69: 33-40.
24. Avnet S, Sciacca L, Salerno M, et al. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res. 2009; 69: 2443-2452.
25. Kim J, Kim ES, Liu D, et al. Comprehensive analysis of expression patterns of insulin-like growth factor and Src pathway in patients with non-small cell lung cancer: two large, independent series of tissue microarray. J Clin Oncol. 2010; 28: 15s (abstr 10531).
26. Gualberto A, Dolled-Filhart M, Gustavson M, et al. Molecular analysis of non-small cell lung cancer (NSCLC) identifies subsets with different sensitivity to insulin like growth factor I receptor (IGF-IR) inhibition. Clin Cancer Res. 2010; 16: 4654-4665.
27. Zhang H, Pelzer AM, Kiang DT, Yee D,. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res. 2007; 67: 391-397.
28. Fulzele K, DiGirolamo DJ, Liu Z, Xu J, Messina JL, Clemens TL,. Disruption of the insulin-like growth factor type 1 receptor in osteoblasts enhances insulin signaling and action. J Biol Chem. 2007; 282: 25649-25658.
29. Ulanet DB, Ludwig DL, Kahn CR, Hanahan D,. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci USA. 2010; 107: 10791-10798.
30. Karp DD, Paz-Ares LG, Novello S, et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol. 2009; 27: 2516-2522.
31. Haluska P, Carboni JM, Loegering DA, et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res, 2006; 66: 362-371.
32. Buck E, Gokhale PC, Koujak S, et al. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther. 2010; 9: 2652-2664.
33. Sabbatini P, Rowand JL, Groy A, et al. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. Clin Cancer Res. 2009; 15: 3058-3067.
34. Wahner Hendrickson AE, Haluska P, Schneider PA, et al. Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res. 2009; 69: 7635-7643.
35. Wood ER, Shewchuk L, Hassel A, et al. Discovery of an inhibitor of insulin-like growth factor 1 receptor activation: implications for cellular potency and selectivity over insulin receptor. Biochem Pharmacol. 2009; 78: 1438-1447.
36. Dziadziuszko R, Camidge DR, Hirsch FR,. The insulin-like growth factor pathway in lung cancer. J Thorac Oncol. 2008; 3: 815-818.
37. Gridelli C, Rossi A, Bareschino MA, Schettino C, Sacco PC, Maione P,. The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non- small cell lung cancer. Expert Opin Investig Drugs. 2010; 19: 631-639.
38. Mattarocci S, Abbruzzese C, Mileo AM, et al. Intracellular presence of insulin and its phosphorylated receptor in non- small cell lung cancer. J Cell Physiol. 2009; 221: 766-770.